<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04317781</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0646</org_study_id>
    <secondary_id>NCI-2019-03832</secondary_id>
    <secondary_id>2018-0646</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT04317781</nct_id>
  </id_info>
  <brief_title>Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant</brief_title>
  <official_title>Tagraxofusp (SL-401) Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients Post-Autologous or Post-Allogeneic Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects of tagraxofusp in treating patients with blastic&#xD;
      plasmacytoid dendritic cell neoplasm after stem cell transplant. Tagraxofusp is a type of&#xD;
      immunotoxin that is made by linking a protein called IL-3 to a toxic substance. Tagraxofusp&#xD;
      may help find cancer cells that express IL-3 and kill them without harming normal cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the safety of tagraxofusp-erzs (tagraxofusp) in patients with blastic&#xD;
      plasmacytoid dendritic cell neoplasm (BPDCN) after autologous (auto) or allogeneic (allo)&#xD;
      hematopoietic cell transplantation (HCT).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate progression-free survival (PFS) in patients with BPDCN receiving maintenance&#xD;
      therapy with tagraxofusp after auto-HCT or allo-HCT.&#xD;
&#xD;
      II. To estimate the overall survival (OS) in patients with BPDCN receiving maintenance&#xD;
      therapy with tagraxofusp after auto-HCT or allo-HCT.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Within day 45 and 120 after stem cell transplant, patients receive tagraxofusp-erzs&#xD;
      intravenously (IV) over 15 minutes on days 1-3 of cycles 1-4 and days 1-2 of subsequent&#xD;
      cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for up to 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of tagraxofusp post-stem cell transplantation (SCT)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Tolerability is defined as receipt of at least 75% of planned tagraxofusp doses in at least 4 cycles of therapy. The percentage of patients considered 'tolerating' will be presented along with the associated 95% exact confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From treatment start date to date of disease progression or death, assessed up to 1 year</time_frame>
    <description>Will be estimated using the Kaplan-Meier method. Median PFS as well as rates with corresponding 95% confidence intervals will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From treatment start date to death, assessed up to 1 year</time_frame>
    <description>Will be estimated using the Kaplan-Meier method. Median OS as well as rates with corresponding 95% confidence intervals will be presented.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Blastic Plasmacytoid Dendritic Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Treatment (tagraxofusp-erzs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within day 45 and 120 after stem cell transplant, patients receive tagraxofusp-erzs IV over 15 minutes on days 1-3 of cycles 1-4 and days 1-2 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tagraxofusp-erzs</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tagraxofusp-erzs)</arm_group_label>
    <other_name>Diphtheria Toxin(388)-Interleukin-3 Fusion Protein</other_name>
    <other_name>DT(388)-IL3 Fusion Protein</other_name>
    <other_name>DT388IL3 fusion protein</other_name>
    <other_name>Elzonris</other_name>
    <other_name>IL3R-targeting Fusion Protein SL-401</other_name>
    <other_name>SL-401</other_name>
    <other_name>TAGRAXOFUSP</other_name>
    <other_name>Tagraxofusp ERZS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible patients will be aged &gt;= 18 years. Pediatric patients age 2 years and older&#xD;
             will be considered on a case by case basis.&#xD;
&#xD;
          -  Diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) according to World&#xD;
             Health Organization (WHO) classification or confirmed by hematopathology&#xD;
&#xD;
          -  The patients must be in partial response or better&#xD;
&#xD;
          -  &gt; 30 days post-transplant without active or chronic infections&#xD;
&#xD;
          -  Karnofsky performance status &gt;= 60%; Lansky &gt;= 60&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;= institutional lower limit of normal by&#xD;
             multigated acquisition (MUGA) scan or echocardiogram within 30 days of first protocol&#xD;
             treatment&#xD;
&#xD;
          -  Diffusion capacity of the lung for carbon monoxide (DLCO) &gt; 40% of predicted value&#xD;
             (corrected for hemoglobin) within 3 months of registration&#xD;
&#xD;
          -  Forced expiratory volume in 1 second (FEV1) &gt; 40% of predicted value within 3 months&#xD;
             of registration&#xD;
&#xD;
          -  Forced vital capacity (FVC) &gt; 40% of predicted value within 3 months of registration&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 mg/dL (133 mmol/L)&#xD;
&#xD;
          -  Serum albumin &gt;= 3.2 g/dL (or &gt;= 32 g/L) without IV albumin within the previous 72&#xD;
             hours&#xD;
&#xD;
          -  Bilirubin =&lt; 1.5 x the upper limit of normal ([ULN] except patients with Gilbert&#xD;
             syndrome in whom bilirubin level of &gt; 1.5 x ULN will be allowed)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 2.5 times ULN&#xD;
&#xD;
          -  Hemoglobin &gt;= 8 g/dL with or without transfusion in the last 7 days&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1000 without granulocyte colony stimulating factor&#xD;
             (GCSF) or granulocyte-macrophage colony-stimulating factor (GMCSF) in the last 2 weeks&#xD;
             prior to screening&#xD;
&#xD;
          -  Platelets &gt;= 50,000micro/mL&#xD;
&#xD;
          -  For allo-HCT, no &gt;= grade 2 visceral (gut or liver) acute graft versus host disease&#xD;
             (GVHD) and no &gt;= grade 3 or any other acute GVHD (patients with chronic GVHD will be&#xD;
             allowed at the discretion of the investigator)&#xD;
&#xD;
          -  Patient agrees to use acceptable contraceptive methods for the duration of time in the&#xD;
             study, and to continue to use acceptable contraceptive methods for 2 months after the&#xD;
             last tagraxofusp infusion&#xD;
&#xD;
          -  Woman of child bearing potential (WOCBP) with a negative serum or urine pregnancy test&#xD;
             within 14 days of tagraxofusp treatment&#xD;
&#xD;
          -  Patient or patient's legal representative, parent(s) or guardian able to sign informed&#xD;
             consent&#xD;
&#xD;
          -  The patient can adhere to the study visit schedule and other protocol requirements,&#xD;
             including follow-up for survival assessment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has persistent clinically significant non-hematologic toxicities &gt;= grade&#xD;
             2 (excluding alopecia, nausea, and fatigue)&#xD;
&#xD;
          -  Evidence of central nervous system (CNS) involvement&#xD;
&#xD;
          -  Uncontrolled and active pulmonary disease&#xD;
&#xD;
          -  Requirement for oxygen treatment&#xD;
&#xD;
          -  Receiving chemotherapy, radiotherapy or other anti-cancer therapy within 14 days of&#xD;
             first dose of study drug. There must be at least a 6-week interval from the last&#xD;
             immunotherapy therapy&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)/hepatitis B and/or C&#xD;
&#xD;
          -  Any history of invasive malignancy in the last 2 years excluding any malignancy such&#xD;
             as cervical cancer or skin cancer (excluding melanoma) that is considered cured at the&#xD;
             time of screening&#xD;
&#xD;
          -  Pregnant or breast-feeding woman&#xD;
&#xD;
          -  Patient has uncontrolled intercurrent illness or medical/psychiatric condition that&#xD;
             would limit compliance with study requirements or that would in the investigator's&#xD;
             opinion place the patient at an unacceptably high risk for toxicities&#xD;
&#xD;
          -  Clinical significant cardiopulmonary disease including uncontrolled or New York Heart&#xD;
             Association (NYHA) class 3 or 4 congestive heart failure, uncontrolled angina,&#xD;
             uncontrolled hypertension, uncontrolled arrhythmia, myocardial infarction or stroke&#xD;
             within 6 months of first protocol treatment or corrected QT (QTc) &gt; 480 ms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qaiser Bashir</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qaiser Bashir</last_name>
    <phone>713-792-8750</phone>
    <email>qbashir@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qaiser Bashir</last_name>
      <phone>713-792-8750</phone>
    </contact>
    <investigator>
      <last_name>Qaiser Bashir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

